Hubbry Logo
SafroleSafroleMain
Open search
Safrole
Community hub
Safrole
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Safrole
Safrole
Safrole
View on Wikipedia
from Wikipedia
Safrole[1]
Skeletal formula of safrole
Skeletal formula of safrole
Ball-and-stick model of safrole
Ball-and-stick model of safrole
Names
Preferred IUPAC name
5-(Prop-2-en-1-yl)-2H-1,3-benzodioxole
Other names
5-(2-Propenyl)-1,3-benzodioxole
5-Allylbenzo[d][1,3]dioxole
3,4-Methylenedioxyphenyl-2-propene
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
ECHA InfoCard 100.002.133 Edit this at Wikidata
EC Number
  • 202-345-4
KEGG
RTECS number
  • CY2800000
UNII
UN number 3082
  • InChI=1S/C10H10O2/c1-2-3-8-4-5-9-10(6-8)12-7-11-9/h2,4-6H,1,3,7H2 checkY
    Key: ZMQAAUBTXCXRIC-UHFFFAOYSA-N checkY
  • InChI=1/C10H10O2/c1-2-3-8-4-5-9-10(6-8)12-7-11-9/h2,4-6H,1,3,7H2
    Key: ZMQAAUBTXCXRIC-UHFFFAOYAD
  • C=CCc1ccc2OCOc2c1
Properties
C10H10O2
Molar mass 162.188 g·mol−1
Density 1.096 g/cm3
Melting point 11 °C (52 °F; 284 K)
Boiling point 232 to 234 °C (450 to 453 °F; 505 to 507 K)
−97.5×10−6 cm3/mol
Hazards
GHS labelling:
GHS07: Exclamation markGHS08: Health hazard
Danger
H302, H341, H350
P201, P281, P308+P313
Legal status
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Safrole is a possibly-carcinogenic,[6] organic compound with the formula CH2O2C6H3CH2CH=CH2. It is a colorless oily liquid, although impure samples can appear yellow. A member of the phenylpropanoid family of natural products, it is found in sassafras plants, among others. Small amounts are found in a wide variety of plants, where it functions as a natural antifeedant.[7] Ocotea pretiosa,[8] which grows in Brazil, and Sassafras albidum,[7] which grows in eastern North America, are the main natural sources of safrole. It has a characteristic "sweet-shop" aroma.

It is a precursor in the synthesis of the insecticide synergist piperonyl butoxide, the fragrance piperonal via isosafrole, and the empathogenic/entactogenic substance MDMA.

Sassafras albidum

History

[edit]

Safrole was obtained from a number of plants, but especially from the sassafras tree (Sassafras albidum), which is native to North America, and from Japanese star anise (Illicium anisatum, called shikimi in Japan).[9] In 1844, the French chemist Édouard Saint-Èvre (1817–1879)[10] determined safrole's empirical formula.[11] In 1869, the French chemists Édouard Grimaux (1835–1900) and J. Ruotte investigated and named safrole.[12]: 928  They observed its reaction with bromine, suggesting the presence of an allyl group.[12]: 929  By 1884, the German chemist Theodor Poleck (1821–1906) suggested that safrole was a derivative of benzene, to which two oxygen atoms were joined as epoxides (cyclic ethers).[13]

In 1885, the Dutch chemist Johann Frederik Eijkman (1851–1915) investigated shikimol, the essential oil that is obtained from Japanese star anise, and he found that, upon oxidation, shikimol formed piperonylic acid,[14]: 39–40  whose basic structure had been determined in 1871 by the German chemist Wilhelm Rudolph Fittig (1835–1910) and his student, the American chemist Ira Remsen (1846–1927).[15] Thus, Eijkman inferred the correct basic structure for shikimol.[14]: 40–41  He also noted that shikimol and safrole had the same empirical formula and had other similar properties, and thus he suggested that they were probably identical.[14]: 41–42  In 1886, Poleck showed that upon oxidation, safrole also formed piperonylic acid, and thus shikimol and safrole were indeed identical.[16] It remained to be determined whether the molecule's C3H5 group was a propenyl group (R−CH=CH−CH3) or an allyl group (R−CH2−CH=CH2). In 1888, the German chemist Julius Wilhelm Brühl (1850–1911) determined that the C3H5 group was an allyl group.[17]

Natural occurrence

[edit]

Safrole is the principal component of brown camphor oil made from Ocotea pretiosa,[8] a plant growing in Brazil, and sassafras oil made from Sassafras albidum.

In the United States, commercially available culinary sassafras oil is usually devoid of safrole due to a rule passed by the US FDA in 1960.[18]

Safrole can be obtained through natural extraction from Sassafras albidum and Ocotea cymbarum. Sassafras oil for example is obtained by steam distillation of the root bark of the sassafras tree. The resulting steam distilled product contains about 90% safrole by weight. The oil is dried by mixing it with a small amount of anhydrous calcium chloride. After filtering-off the calcium chloride, the oil is vacuum distilled at 100 °C under a vacuum of 11 mmHg (1.5 kPa) or frozen to crystallize the safrole out. This technique works with other oils in which safrole is present as well.[19][20]

Safrole is typically extracted from the root-bark or the fruit of Sassafras albidum[7] (native to eastern North America) in the form of sassafras oil, or from Ocotea odorifera,[8] a Brazilian species. Safrole is also present in certain essentials oils and in brown camphor oil, which is present in small amounts in many plants. Safrole can be found in anise, nutmeg, cinnamon, and black pepper. The safrole content of perfume, cologne, and toilet water can be determined by dilution with ethanol, followed by separation using high-performance liquid chromatography. and quantization using spectrophotofluorometry[21]

Applications

[edit]

Safrole is a member of the methylenedioxybenzene group, of which many compounds are used as insecticide synergists; for example, safrole is used as a precursor in the synthesis of the insecticide piperonyl butoxide. Safrole is also used as a precursor in the synthesis of the drug ecstasy (MDMA, 3,4-methylenedioxymethamphetamine). Before safrole was banned by the US FDA in 1960 for use in food, it was used as a food flavor for its characteristic 'candy-shop' aroma. It was used as an additive in root beer, chewing gum, toothpaste, soaps, and certain pharmaceutical preparations.

Safrole exhibits antibiotic[22] and anti-angiogenic[23] functions.

Synthesis

[edit]

It can be synthesized from catechol[20] first by conversion to methylenedioxybenzene, which is brominated and coupled with allyl bromide.[24]

Safrole is a versatile precursor to many compounds. Examples are N-acylarylhydrazones and isosters,[25] aryl-sulfonamide derivatives,[26] acidic sulfonylhydrazone derivatives,[27] benzothiazine derivatives[28] and many more.

Isosafrole

[edit]
Main article: Isosafrole

Isosafrole is produced synthetically from safrole. It is not found in nature. Isosafrole comes in two forms, trans-isosafrole and cis-isosafrole. Isosafrole is used as a precursor for the psychoactive drug MDMA (ecstasy). When safrole is metabolized, several metabolites can be identified. Some of these metabolites have been shown to exhibit toxicological effects, such as 1′-hydroxysafrole and 3′-hydroxysafrole in rats. Further metabolites of safrole that have been found in urine of both rats and humans include 1,2-dihydroxy-4-allylbenzene or 1(2)-methoxy-2(1)hydroxy-4-allylbenzene.[29]

Metabolism

[edit]

Safrole can undergo many forms of metabolism. The two major routes are the oxidation of the allyl side chain and the oxidation of the methylenedioxy group.[30] The oxidation of the allyl side chain is mediated by a cytochrome P450 complex, which will transform safrole into 1′-hydroxysafrole. The newly formed 1′-hydroxysafrole will undergo a phase II drug metabolism reaction with a sulfotransferase enzyme to create 1′-sulfoxysafrole, which can cause DNA adducts.[31] A different oxidation pathway of the allyl side chain can form safrole epoxide. So far, this has only been found in rats and guinea pigs. The formed epoxide is a small metabolite due to the slow formation and further metabolism of the compound. An epoxide hydratase enzyme will act on the epoxide to form dihydrodiol, which can be secreted in urine.[citation needed]

The metabolism of safrole through the oxidation of the methylenedioxy proceeds via the cleavage of the methylenedioxy group. This results in two major metabolites: allylcatechol and its isomer, propenylcatechol. Eugenol is a minor metabolite of safrole in humans, mice, and rats. The intact allyl side chain of allylcatechol may then be oxidized to yield 2′,3′-epoxypropylcatechol. This can serve as a substrate for an epoxide hydratase enzyme, and will hydrate the 2′,3′-epoxypropylcatechol to 2′,3′-dihydroxypropylcatechol. This new compound can be oxidized to form propionic acid (PPA),[30] which is a substance that is related to an increase in oxidative stress and glutathione S-transferase activity. PPA also causes a decrease in glutathione and Glutathione peroxidase activity.[32] The epoxide of allylcatechol may also be generated from the cleavage of the methylenedioxy group of the safrole epoxide. The cleavage of the methylenedioxy ring and the metabolism of the allyl group involve hepatic microsomal mixed-function oxidases.[30]

Toxicity

[edit]

Toxicological studies have shown that safrole is a weak hepatocarcinogen at higher doses in rats and mice. Safrole requires metabolic activation before exhibiting toxicological effects.[30] Metabolic conversion of the allyl group in safrole is able to produce intermediates which are directly capable of binding covalently with DNA and proteins. Metabolism of the methylenedioxy group to a carbene allows the molecule to form ligand complexes with cytochrome P450 and P448. The formation of this complex leads to lower amounts of available free cytochrome P450. Safrole can also directly bind to cytochrome P450, leading to competitive inhibition. These two mechanisms result in lowered mixed function oxidase activity.

Furthermore, because of the altered structural and functional properties of cytochrome P450, loss of ribosomes which are attached to the endoplasmic reticulum through cytochrome P450 may occur.[29] The allyl group thus directly contributes to mutagenicity, while the methylenedioxy group is associated with changes in the cytochrome P450 system and epigenetic aspects of carcinogenicity.[29] In rats, safrole and related compounds produced both benign and malignant tumors after intake through the mouth. Changes in the liver are also observed through the enlargement of liver cells and cell death.

In the United States, it was once widely used as a food additive in root beer, sassafras tea, and other common goods, but was banned for human consumption by the FDA after studies in the 1960s suggested that safrole was carcinogenic, causing permanent liver damage in rats;[33][34][35] food products sold there purporting to contain sassafras instead contain a safrole-free sassafras extract. Safrole is also banned for use in soap and perfumes by the International Fragrance Association.

According to a 1977 study of the metabolites of safrole in both rats and humans, two carcinogenic metabolites of safrole found in the urine of rats, 1′-hydroxysafrole and 3′-hydroxyisosafrole, were not found in human urine.[36] The European Commission on Health and consumer protection assumes safrole to be genotoxic and carcinogenic.[37] It occurs naturally in a variety of spices, such as cinnamon, nutmeg, and black pepper, and herbs such as basil. In that role, safrole, like many naturally occurring compounds, may have a small but measurable ability to induce cancer in rodents. Despite this, the effects in humans were estimated by the Lawrence Berkeley National Laboratory to be similar to risks posed by breathing indoor air or drinking municipally supplied water.[38]

Adverse effects

[edit]

Besides being a hepatocarcinogen, safrole exhibits further adverse effects in that it will induce the formation of hepatic lipid hydroperoxides.[35] Safrole also inhibits the defensive function of neutrophils against bacteria. In addition to the inhibition of the defensive function of neutrophils, it has also been discovered that safrole interferes with the formation of superoxides by neutrophils.[22] Furthermore, safrole oxide, a metabolite of safrole, has a negative effect on the central nervous system. Safrole oxide inhibits the expression of integrin β4/SOD, leading to apoptosis of the nerve cells.[39]

Use in MDMA manufacture

[edit]
MDMA synthesis from safrole

Safrole is listed as a Table I precursor under the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.[4] Due to their role in the manufacture of MDMA, safrole, isosafrole, and piperonal are Category I precursors under regulation no. 273/2004 of the European Community.[5] In the United States, safrole is currently a List I chemical.[3]

The root bark of American sassafras contains a low percentage of steam-volatile oil, which is typically 75% safrole.[40] Attempts to refine safrole from sassafras bark in mass quantities are generally not economically viable due to low yield and high effort. However, smaller quantities can be extracted quite easily via steam distillation (about 10% of dry sassafras root bark by mass, or about 2% of fresh bark).[19] Demand for safrole is causing rapid and illicit harvesting of the Cinnamomum parthenoxylon tree in Southeast Asia, in particular the Cardamom Mountains in Cambodia.[41] However, it is not clear what proportion of illicitly harvested safrole is going toward MDMA production, as over 90% of the global safrole supply (about 2,000 tonnes or 2,200 short tons per year) is used to manufacture pesticides, fragrances, and other chemicals.[42][43] Sustainable harvesting of safrole is possible from leaves and stems of certain plants, including the roots of camphor seedlings.[42][43]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Safrole

View on Grokipedia
from Grokipedia

Safrole is a naturally occurring with the molecular formula C₁₀H₁₀O₂, belonging to the class of phenylpropenes and characterized as 5-(prop-2-en-1-yl)-1,3-benzodioxole. It manifests as a clear, colorless to pale yellow oily liquid with a of 1.09 g/cm³, insoluble in , and possessing a distinctive akin to sassafras root. The compound is chiefly derived from the essential oil of the tree (), comprising 80–90% of sassafras root bark oil, and occurs in smaller quantities in essential oils from plants such as Ocotea pretiosa, , , , and mace. Safrole was historically employed as a flavoring agent in beverages like root beer and in perfumes due to its aromatic profile, but its direct addition to food or use in human food has been prohibited by the U.S. Food and Drug Administration since 1960 following demonstrations of hepatocarcinogenicity in rodent studies involving oral administration at levels of 0.5–1% in diet. These studies revealed dose-dependent liver tumor induction, attributed to metabolic activation via cytochrome P450 enzymes forming proximate carcinogens like 1'-hydroxysafrole, which generate DNA adducts. Commercially, safrole functions as a precursor for synthesizing , a synergist enhancing insecticides by inhibiting detoxification, and for (heliotropin), a vanilla-like fragrance used in perfumery. Its conversion to 3,4-methylenedioxyphenyl-2-propanone (PMK), an intermediate in production, has prompted classification as a DEA List I chemical, subjecting handlers to stringent reporting and record-keeping to curb diversion for clandestine synthesis. The U.S. National Toxicology Program lists safrole as reasonably anticipated to be a carcinogen, grounded in sufficient from animal bioassays showing hepatic neoplasms in multiple , including mice more susceptible than rats, though direct human data remain absent and natural dietary exposure levels are typically low.

Chemical Identity and Properties

Molecular Structure and Physical Characteristics

Safrole has the molecular formula C10H10O2 and a of 162.19 g/mol. Its IUPAC name is 5-(prop-2-en-1-yl)-2H-1,3-benzodioxole, reflecting a benzene ring fused to a 1,3-dioxole ring (forming the moiety at positions 1 and 2) with an allyl (-CH2-CH=CH2) attached at position 5. This structure contributes to its aromatic and ether-like functional groups, enabling applications in fragrance synthesis prior to regulatory restrictions. At standard conditions, safrole manifests as a clear, colorless to slightly liquid with a distinctive odor. It possesses a density of 1.099 g/mL at 20 °C, making it denser than , and exhibits low solubility of approximately 0.012 g/100 mL at 25 °C, though it dissolves readily in organic solvents such as and . Key thermal properties include a of 11.2 °C and a of 232–234 °C at , with a of 1.537 at 20 °C and of 1 mm Hg at 63.8 °C.
PropertyValue
Density (20 °C)1.099 g/mL
Melting point11.2 °C
Boiling point232–234 °C
Refractive index (20 °C)nD 1.537
Water solubility (25 °C)0.012 g/100 mL
Isosafrole, an of safrole produced via base-catalyzed of the allyl , serves as a key intermediate in the synthesis of (heliotropin), a fragrance compound obtained through oxidative cleavage of its propenyl group. is also converted to 3,4-methylenedioxyphenyl-2-propanone (MDP2P) via oxidation, with MDP2P acting as the immediate precursor to 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine () through . Dihydrosafrole, formed by catalytic of safrole's , exhibits hepatic profiles akin to safrole, including cell degeneration and nodular in studies, though it lacks the unsaturated reactivity of its parent compound. , an synergist, is synthesized from safrole through a multi-step process involving side-chain modification and ether formation, enhancing the efficacy of pyrethroids by inhibiting enzymes in . Other derivatives, such as 1-hydroxysafrole from metabolic oxidation, have been identified in mammalian pathways and contribute to safrole's overall carcinogenicity, with the of 1-hydroxysafrole acting as a proximate hepatocarcinogen in .

Natural Occurrence and

Primary Plant Sources

Safrole occurs naturally as a major component in the essential oils of select plants, primarily within the and families. The most significant commercial and historical source is the root bark of Sassafras albidum, a native to eastern , where steam-distilled oil contains 80-90% safrole. This high concentration made sassafras oil a primary feedstock for safrole extraction until regulatory restrictions in the mid-20th century. Another key source is Ocotea pretiosa (syn. Ocotea odorifera), known as Brazilian sassafras, endemic to Brazil's . Essential oil from its wood and bark exhibits high safrole levels, historically comprising up to 90% of the distillate, positioning it as a leading alternative after North American harvesting declined. In the Piperaceae family, Piper hispidinervum (long-pepper) stands out, with leaf essential oil yielding 80-90% safrole, cultivated in Brazil and Peru as a sustainable, high-output source since the 1990s. Other Piper species, such as P. divaricatum and P. callosum, contain substantial safrole in leaves (up to 98%), fruits (87%), and stems (83%), though yields vary by provenance and extraction method. Minor sources include Cinnamomum camphora ( tree) brown oil (around 80% safrole from root stumps) and trace amounts in spices like and , but these are not primary due to lower concentrations or secondary status. Overall, species dominate traditional extraction, while offer emerging, agriculturally viable options with comparable purity.

Biosynthetic Pathways

Safrole is biosynthesized primarily in the specialized tissues of plants such as Sassafras albidum and Ocotea pretiosa through a branch of the phenylpropanoid pathway, which derives from L-phenylalanine generated via the shikimate pathway in plastids. The pathway commences with the deamination of L-phenylalanine to trans-cinnamic acid, catalyzed by phenylalanine ammonia-lyase (PAL), marking the entry point into secondary metabolism. Subsequent transformations include sequential hydroxylations at the 3- and 4-positions of the aromatic ring by P450-dependent monooxygenases, yielding (3,4-dihydroxycinnamic acid). The characteristic methylenedioxy bridge of the 1,3-benzodioxole moiety is formed from this precursor via enzymatic cyclization, potentially incorporating a one-carbon unit analogous to processes in . The propenoic side chain undergoes reduction to the corresponding alcohol, followed by and double-bond migration to produce the terminal , steps facilitated by reductases, dehydratases, and isomerases similar to those in the formation of related phenylpropenes like methyleugenol and . These modifications occur downstream of monolignol intermediates, diverging from biosynthesis, and involve acyltransferases (e.g., BAHD family) for transient acetylation to enable Claisen-type rearrangements yielding the allyl configuration. While the core phenylpropanoid enzymes like PAL and cinnamate 4-hydroxylase (C4H) are conserved across , species-specific isoforms and synthases tailor the pathway for safrole accumulation, often upregulated in response to developmental cues or stress. Detailed enzymatic characterization remains limited, with ongoing research focusing on transcriptomic and in safrole-producing species like relatives to identify unique steps.

Historical Development

Early Discovery and Traditional Uses

Native American tribes in eastern employed infusions and teas prepared from the root bark of , which contains up to 90% safrole in its , for treating fevers, , , and other ailments long before European contact. The aromatic qualities of safrole-rich were also harnessed for flavoring beverages, including precursors to , and as a natural or fragrance in traditional practices. Upon European exploration in the late , root bark, valued for its safrole-derived scent and purported medicinal virtues, became a significant exported to , where it was touted as a cure for , , and various infections during the colonial era. of oil, yielding safrole as its dominant component, emerged in the early , facilitating its recognition as the key volatile responsible for the plant's characteristic odor and flavor. By the mid-19th century, safrole's chemical properties were further elucidated through organic analysis, confirming its structure as 5-(2-propenyl)-1,3-benzodioxole and enabling targeted extraction via for use in perfumes, soaps, and food flavorings. Traditional uses persisted in folk medicine and culinary applications, such as from dried leaves for thickening gumbos, underscoring safrole's role in pre-industrial pharmacopeia despite lacking rigorous empirical validation at the time.

Industrial Adoption and Peak Usage (19th-20th Century)

Safrole's industrial adoption accelerated in the mid-19th century amid rising demand for natural aromatic compounds in the expanding flavor and fragrance sectors. Extracted primarily via steam distillation from the roots of Sassafras albidum, sassafras oil—containing 80-90% safrole—provided a cost-effective source for its distinctive sweet-spicy profile, evoking root beer and anise-like notes. This period saw initial commercialization in North American beverages, with root beer formulations incorporating safrole-rich extracts as a core flavorant, aligning with innovations in carbonation and bottling that transitioned homemade tonics to mass-produced goods by the 1870s. Peak usage materialized in the early , driven by safrole's versatility in foodstuffs, , and perfumery applications. It flavored soft drinks, gums, and toothpastes, capitalizing on its 'candy-shop' aroma, while serving as a precursor for (heliotropin) through oxidation processes, yielding a substitute for broader flavor synthesis. U.S. production of sassafras oil intensified to meet this demand, though it began declining post-1910 due to cheaper Japanese imports of safrole-containing Cinnamomum oils, shifting reliance toward synthetic derivatives and alternative sources like Brazilian Ocotea cymbarum. Global output of safrole-rich oils escalated accordingly, with estimates indicating substantial volumes supporting fragrance and soap manufacturing before regulatory scrutiny emerged. In regions like , wartime needs briefly boosted localized extraction, peaking at 660 pounds of sassafras oil in 1943-44 from state forests, underscoring safrole's strategic value in supply chains. By mid-century, annual natural safrole production approached thousands of tons, primarily for legitimate non-consumptive ends like piperonyl butoxide insecticides and aromatic chemicals, before food-use bans curtailed broader applications.

Post-1960 Regulatory Shifts

In 1960, the United States Food and Drug Administration (FDA) banned safrole, along with sassafras oil (containing approximately 80% safrole), isosafrole, and dihydrosafrole, from use as direct or indirect food additives. This action, effective December 3, 1960, followed animal studies in which oral administration of safrole at doses of 100–500 mg/kg body weight induced liver tumors in rats, prompting invocation of the Delaney Clause under the Federal Food, Drug, and Cosmetic Act, which prohibits any additive demonstrated to cause cancer in test animals irrespective of human relevance or exposure levels. The prohibition encompassed commercial applications such as flavoring in and tea, effectively curtailing sassafras-derived products in the food supply. Subsequent regulatory scrutiny intensified due to safrole's established role as a key precursor in the clandestine synthesis of 3,4-methylenedioxymethamphetamine (, commonly known as ecstasy). The (DEA) classified safrole as a List I chemical under the , mandating registration, record-keeping, importation/exportation declarations, and theft reporting for manufacturers, distributors, importers, and exporters to prevent diversion. This designation, codified in 21 CFR 1310.02, reflects safrole's chemical code 8323 and aligns with controls implemented amid rising trafficking in the and . Internationally, safrole faces analogous restrictions as a Table I precursor under the 1988 Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, requiring monitoring of trade to curb illicit drug production. The International Fragrance Association (IFRA) further prohibits its use in cosmetics, soaps, and perfumes to mitigate potential health risks. In the , Regulation (EC) No 273/2004 imposes licensing and reporting for safrole handling, while the International Agency for Research on Cancer (IARC) has classified safrole as "possibly carcinogenic to humans" (Group 2B) since 1976 based on limited human evidence and sufficient animal data. These measures collectively shifted safrole from a permissible flavorant to a heavily , prioritizing precursor diversion prevention over prior industrial tolerances.

Production Methods

Natural Extraction Techniques

Safrole is primarily extracted from the root bark of the (), a species native to eastern , through , which yields an containing 80-90% safrole. The process involves grinding the dried root bark into small particles to increase surface area, then subjecting the material to steam in a distillation apparatus, where the volatile safrole vaporizes and condenses separately from the aqueous phase as an oily layer. This method leverages the compound's volatility and immiscibility with water, typically requiring several hours of distillation for optimal yield, with fresh root bark preferred to maximize oil recovery. Hydrodistillation represents a variant technique, involving boiling the root bark in water to generate in situ, resulting in sassafras oil with safrole content around 82.82%. Both and hydrodistillation are efficient for industrial-scale extraction due to their and avoidance of organic solvents, though yields can vary based on plant age, harvesting season, and bark preparation, with chipped improving efficiency and reducing time. Post-, the crude oil undergoes under reduced pressure to enrich safrole purity, often exceeding 90%, as described in processes for separating it from accompanying like and . Natural extraction from alternative sources, such as the bark of Ocotea cymbarum in , follows similar protocols, producing safrole-rich oils used historically in fragrance industries before regulatory restrictions. These techniques prioritize thermal volatilization over solvent-based methods to maintain the "natural" designation, though modern enrichments may incorporate ionic liquids for selective safrole recovery from the without altering the initial plant extraction step. Environmental concerns, including overharvesting of trees, have diminished reliance on these methods since the mid-20th century.

Synthetic Routes and Challenges

One principal synthetic route to safrole involves the Friedel-Crafts alkylation of 1,3-benzodioxole with in the presence of a catalyst such as Nafion-H, proceeding via at the 5-position to yield safrole in up to 80% isolated yield under mild conditions (50–60°C, 4–6 hours). This one-step process leverages the directing effect of the group for and benefits from the catalyst's recyclability (up to five cycles with minimal activity loss), reducing waste compared to homogeneous acid systems. Alternative multi-step syntheses begin with (1,2-benzenediol), which is cyclized to 1,3-benzodioxole using and a base like KOH or NaOH at elevated temperatures (around 100–120°C), followed by selective bromination at the 5-position with N-bromosuccinimide (NBS) in acetic acid or in (yields 70–90%), and subsequent allylation via a with and magnesium in (overall yield approximately 50–60%). These routes avoid direct pitfalls but require anhydrous conditions for the organometallic step. Challenges in safrole synthesis include side chain isomerization to under acidic or thermal stress, which reduces yield of the desired allyl isomer (typically requiring separation at 232–234°C under reduced pressure), and polyalkylation in unsubstituted Friedel-Crafts variants using AlCl3 or BF3, necessitating excess arene or protective groups. Grignard-based methods demand rigorous exclusion of moisture and oxygen, leading to inconsistent yields and material waste. Moreover, safrole's classification as a Schedule I controlled substance precursor in the United States (since 1970s DEA listings) and similar restrictions in the impose regulatory hurdles on scaling production, including precursor monitoring (e.g., 1,3-benzodioxole as a watched chemical), forensic tracing of impurities for illicit diversion detection, and compliance with cGMP standards for any legitimate applications, often favoring natural extraction despite its limitations.

Legitimate Industrial Applications

Fragrance, Flavor, and Perfumery Uses

Safrole, a phenylpropanoid compound abundant in sassafras root bark oil (up to 93% composition), imparts a distinctive spicy, -like aroma historically prized in flavorings. It served as a primary in and other beverages, as well as in candies, gums, and toothpastes, until banned by the U.S. on December 1, 1960, following studies demonstrating hepatocarcinogenicity at doses equivalent to prolonged high human exposure. Post-ban, synthetic alternatives like sassafras essences (safrole-depleted extracts) or blends replicate its flavor profile in commercial s without the compound itself. In perfumery, safrole functions indirectly as a precursor to heliotropin (), synthesized via and oxidation, yielding a sweet, heliotrope scent used in floral and oriental fragrances since the late . Heliotropin, derived from safrole, appears in formulations for soaps, lotions, and fine perfumes, contributing notes akin to , , and , with annual global production exceeding 10,000 metric tons as of the early 2000s. Direct incorporation of safrole into non-consumable fragrances persists in trace amounts within certain blends from , mace, and , valued for their warm, woody undertones, though regulatory scrutiny limits concentrations to below carcinogenic thresholds established by bodies like the International Fragrance Association. These applications leverage safrole's volatile methylenedioxybenzene structure, which enhances fixation and diffusion in perfume accords, but production has shifted toward sustainable botanical alternatives like Piper hispidinervum oil (70-90% safrole content) to mitigate risks from harvesting. Despite health concerns, peer-reviewed toxicological data affirm low dermal absorption and minimal risk in diluted perfumery contexts, contrasting with oral profiles that prompted flavor bans.

Other Non-Consumptive Applications

Safrole functions as a chemical precursor in the industrial production of , a semisynthetic compound serving as a synergist in formulations. enhances the efficacy of pyrethrum-derived and synthetic by inhibiting monooxygenases in , thereby blocking the metabolic of these active agents. This application underscores safrole's utility in products, where it contributes to formulations used in , , and household applications since the compound's development in the . The synthesis route from safrole to typically proceeds via to , followed by oxidative cleavage to yield (heliotropin), an intermediate that undergoes further and etherification to form the final synergist. This multi-step exploits safrole's allylbenzene structure, enabling efficient conversion under controlled industrial conditions, though yields and purity are influenced by reaction parameters such as catalysts and temperature. Despite safrole's classification as a controlled precursor due to diversion risks, its role in manufacture remains a legitimate non-consumptive outlet, with global production of the synergist exceeding thousands of metric tons annually for use.

Illicit and Restricted Applications

Precursor Role in MDMA Synthesis

Safrole serves as a primary precursor in the illicit synthesis of MDMA (3,4-methylenedioxymethamphetamine), commonly known as ecstasy, due to its structural relation to the methylenedioxyphenyl ring system essential for the drug's pharmacophore. In typical clandestine production, safrole is first isomerized to isosafrole using a base catalyst such as potassium hydroxide, yielding nearly quantitative conversion under reflux conditions. Isosafrole is then oxidized to 3,4-methylenedioxyphenyl-2-propanone (MDP2P or PMK), the key intermediate, via methods like Wacker oxidation with palladium chloride and copper chloride in the presence of oxygen, or alternative peracid oxidations such as performic or peracetic acid, achieving yields of 50-80% depending on scale and purity. MDP2P undergoes with and a , such as aluminum amalgam (Al/Hg) or , to form the final product, often as the hydrochloride salt after acidification and extraction, with overall yields from safrole reported up to 60-70% in optimized laboratory settings. This route traces back to early 20th-century patents, including Merck's 1914 method involving safrole bromination followed by amination, though modern illicit labs favor the PMK pathway for its efficiency and accessibility from natural safrole-rich oils like or camphor sources containing up to 90% safrole. Alternative precursors like can substitute but safrole remains dominant in global seizures, comprising over 95% of identified MDMA-related precursor samples in forensic analyses. The reliance on safrole underscores its chemical utility, as its allylbenzene structure enables straightforward elaboration to the propanone ketone via and oxidation, bypassing more complex de novo syntheses. However, impurities from natural extraction, such as dihydrosafrole, can carry through, affecting purity and detectable via in seized products. DEA monitoring highlights safrole's diversion risk, with oils directly implicated in large-scale labs due to their high precursor content.

Enforcement and Diversion Risks

Safrole is regulated as a List I chemical by the (DEA) under the , imposing obligations on handlers to prevent diversion to clandestine production. These include mandatory registration, detailed recordkeeping of all domestic and international transactions, verification of customer identities through government-issued identification, and immediate oral reporting of suspicious orders followed by written confirmation within 15 days. Failure to comply exposes handlers to civil, administrative, or criminal penalties, including fines and potential revocation of DEA registration. Diversion risks stem primarily from safrole's essential role as a precursor in synthesis via to and subsequent oxidation steps, prompting criminals to target legitimate industrial supplies or extract it from oil and plants. Suspicious indicators flagged by the DEA include requests for unusual quantities, cash payments, or deliveries to non-standard locations, as criminals exploit any lapses in . A DEA advisory updated as of April 30, 2025, warns that even essential oils rich in safrole (typically 80-90% content) pose equivalent threats, urging handlers to treat them identically to pure safrole. Unwitting diversion can lead to liability under 21 U.S.C. § 843(a)(6) and (7) for distributing knowing or with reasonable cause that it will be used illicitly. Enforcement efforts involve DEA monitoring of imports, exports, and domestic sales, with declarations required at least 15 days in advance for review. Knowing possession or distribution for production constitutes a , punishable by up to 20 years and substantial fines, depending on prior offenses and quantity. Clandestine seizures frequently uncover safrole or oil; for example, resurgences in have linked safrole-based operations to output, while global precursor intercepts, such as 2.7 tonnes of safrole-rich materials seized in the from 2019 to 2021, demonstrate coordinated international disruption of supply chains. These measures have periodically constrained availability, as seen in major Asian seizures exceeding 50 tonnes in 2010, though underground adaptation via alternative routes persists.

Biochemical Metabolism

Metabolic Pathways in Mammals

Safrole is rapidly absorbed from the via passive diffusion in both rats and humans following . In rats, approximately 10-20% of an oral dose is absorbed, with the remainder excreted unchanged in , while in humans, absorption is similarly efficient but limited in extent for higher doses. Once absorbed, safrole undergoes extensive hepatic , primarily via (CYP) enzymes, with over 90% of metabolites excreted in urine within 72 hours in rats. The dominant detoxification pathway in rats involves O-demethylenation of the methylenedioxyphenyl ring, yielding piperonyl derivatives such as 3,4-dihydroxy-1-propenylbenzene conjugates, accounting for about 86% of urinary metabolites. This process is mediated by CYP enzymes and followed by phase II conjugation with glucuronic acid or sulfuric acid for excretion. Minor pathways include allylic oxidation of the side chain to form 1'-hydroxysafrole, a proximate toxicant, and epoxidation to safrole-2',3'-epoxide, which hydrolyzes to diols; these routes represent less than 10% of total metabolism but are critical for bioactivation leading to DNA adducts. In humans, CYP1A2, CYP2A6, and CYP2E1 predominantly catalyze the bioactivation of safrole to 1'-hydroxysafrole via side-chain oxidation, with subsequent sulfonation by sulfotransferases forming a reactive sulfuric acid ester that binds to DNA. Species-specific differences exist; for instance, rats exhibit higher demethylenation rates relative to side-chain oxidation compared to humans, influencing toxicity profiles, as shown in computational models of phase I metabolism across mammals. Overall, mammalian metabolism balances detoxification through ring cleavage and conjugation against bioactivation via the allyl chain, with the latter implicated in safrole's carcinogenicity.

Formation of Metabolites

Safrole is primarily metabolized in the liver through phase I oxidation mediated by cytochrome P450 (CYP) enzymes, with CYP2A6 being the predominant isoform responsible for 1'-hydroxylation in humans, yielding 1'-hydroxysafrole as the key proximate toxicant. This allylic hydroxylation occurs via CYP-dependent insertion of oxygen at the 1' position of the allyl side chain, a process that exhibits species-specific efficiency; for instance, human CYP2A6 facilitates higher formation rates compared to rodent homologs like rat CYP2A3. The resulting 1'-hydroxysafrole serves as a substrate for phase II sulfonation by sulfotransferases, generating an electrophilic 1'-sulfoxy-safrole that can form DNA adducts, though competing detoxification pathways include oxidation to 1'-oxosafrole or glucuronidation/sulfation for urinary excretion. An alternative metabolic route involves epoxidation of the allyl by CYP enzymes to form safrole 2',3'-epoxide, which hydrolyzes to trans-2',3'-dihydroxy- or cis-2',3'-dihydroxy-safrole, eventually yielding 1,2-dihydroxy-4-allylbenzene (also known as dihydroxychavicol) as a major metabolite. This , often conjugated with glucuronic or , constitutes the principal urinary metabolite in humans following , with nearly complete excretion within 24 hours for small doses. In contrast, excrete higher proportions of 1'-hydroxysafrole conjugates (up to 30% in pretreated male mice versus 1-3% in untreated rats), alongside minor metabolites like 3'-hydroxyisosafrole and derivatives. Additional pathways include cleavage of the ring, potentially via CYP-mediated O-demethylenation, producing catecholic compounds such as hydroxychavicol, and side-chain oxidation to carboxylic acids or ketones, though these yield lower quantities in mammals. Pretreatment with inducers like or 3-methylcholanthrene can elevate 1'-hydroxysafrole formation by up to tenfold in rats, highlighting enzymatic inducibility in bioactivation. Overall, profiles differ quantitatively between species, with humans favoring via diol formation over the carcinogenic 1'-hydroxylation branch observed more prominently in .

Toxicity and Health Risks

Evidence from

Safrole has demonstrated hepatocarcinogenic effects in multiple species, primarily through dietary administration. In rats fed safrole at concentrations of 0.5–1% of the diet, liver tumors, including hepatocellular carcinomas, developed after chronic exposure durations of 8–10 months or longer. Similarly, dietary safrole induced in mice, with the species appearing more susceptible than rats to the carcinogenic effects, as evidenced by higher tumor incidence at comparable doses. Subcutaneous injection of safrole also produced liver tumors in both rats and mice, confirming multi-route carcinogenicity in . Metabolic activation plays a central role in safrole's toxicity, with 1'-hydroxysafrole identified as a proximate . When administered to male rats at 0.5% of the diet for 8–10 months, 1'-hydroxysafrole induced a high incidence of hepatocellular carcinomas, exceeding that observed with safrole itself under similar conditions. This metabolite forms DNA adducts in the liver, contributing to and tumor initiation, as supported by studies showing increased mutant frequencies in gpt delta rat models treated with safrole. Beyond carcinogenicity, safrole exhibits acute and subchronic in . In medium-term studies using gpt delta rats, oral safrole administration caused liver damage, including elevated enzyme levels and histopathological changes such as of hepatocytes. Renal was also observed in male rats, with potential increases in rates and DNA damage in tissues following repeated dosing. These effects were dose-dependent, with genotoxic responses evident at levels inducing organ-specific mutations but not uniformly across all endpoints.
Study ModelExposure Route/DoseDurationKey FindingsSource
Male ratsDietary, 0.5% safrole8–10 monthsHepatocellular carcinomas
Mice and ratsDietary, 0.5–1% safroleChronicLiver tumors; higher susceptibility in mice
gpt delta ratsOral, varying dosesMedium-term (13 weeks), increased gpt mutations, renal effects in males

Human Epidemiological Data and Associations

No epidemiological studies have directly evaluated the association between safrole exposure and cancer incidence or other health outcomes in populations. Regulatory classifications of safrole as reasonably anticipated to be a carcinogen rely primarily on data, with evidence limited to biomarkers of exposure rather than prospective or retrospective cohort analyses. Human exposure to safrole occurs primarily through dietary sources such as trace amounts in spices (e.g., , ) and herbal products, with estimated average daily intake around 0.3 mg from natural occurrence. Historical use in beverages like and prior to regulatory bans in the resulted in higher ingestion levels, but no documented cancer clusters or case reports have been linked to these exposures in Western populations. Occupational exposure affects a small number of workers (approximately 6,475 estimated in 1990), mainly via or dermal contact in fragrance or chemical industries, without identified health tying it to . Indirect associations arise from betel quid (areca quid) chewing in regions like Southeast Asia and India, where preparations containing safrole-rich plants (e.g., certain betel inflorescences with up to 15,000 mg/kg safrole) correlate with elevated risks of oral, esophageal, and hepatocellular cancers. Betel quid use is a established risk factor for oral cancer, with odds ratios exceeding 10 in some studies, but this involves multiple genotoxic agents including arecoline and tobacco, confounding safrole's specific contribution. Safrole-DNA adducts, detected via 32P-postlabeling in oral tissues of betel quid-associated oral cancer patients and in peripheral blood leukocytes of 94% of current chewers (versus 13% in non-chewers), indicate systemic exposure and potential genotoxicity at high doses (salivary levels up to 68 mg/L during chewing). However, these biomarkers do not establish causality for cancer development, as human metabolic activation of safrole differs from rodents, and no tumorigenic metabolites have been consistently found in human urine. Beyond cancer, no population-level data link safrole to other epidemiological outcomes like liver damage or reproductive effects.

Dose-Response Considerations and Threshold Debates

In studies, safrole induces liver tumors in a dose-dependent manner, with mice exhibiting greater sensitivity than rats. Dietary administration of 0.5% safrole (approximately 250–500 mg/kg body weight per day) to rats for two years resulted in malignant liver tumors in 14 of 50 animals, establishing a carcinogenic potency (TD50) of 440 mg/kg/day. In mice, the TD50 is lower at 51 mg/kg/day, with perinatal subcutaneous injections (0.52–6.6 mg total dose) or dietary exposure at 0.4–0.5% yielding hepatocellular adenomas, carcinomas, and increased tumor incidence. Lower dietary levels, such as 500 ppm, produced slight but no tumors, indicating a lowest observed effect level (LOEL) around this threshold for non-neoplastic effects. Human exposure to safrole remains far below these tumorigenic doses, primarily from trace amounts in spices like or beverages, estimated at 0.3 mg/day (average) to 0.5 mg/day (high percentile) for consumers, equivalent to 0.004–0.007 mg/kg/day for a 70 kg . This yields margins of exposure exceeding 7,000–100,000-fold relative to TD50 values, suggesting negligible risk under linear models despite safrole's as reasonably anticipated to be a based solely on animal data. No direct epidemiological evidence links low-level safrole exposure to cancer, with historical uses in beverages preceding bans showing no clear causal associations. Debates center on whether safrole's —evidenced by dose-dependent formation in liver persisting up to 140 days—precludes a practical threshold, as assumed by regulatory bodies like the EU Scientific Committee on Food, which rejects a safe intake level due to non-threshold mechanisms. However, safrole's overall low potency as a weak hepatocarcinogen in adult , combined with species-specific metabolic differences (e.g., higher activation in mice), supports arguments for nonlinear dose-response curves where pathways may dominate at low exposures, rendering tumor risks effectively zero below certain pharmacokinetic thresholds. Critics of strict no-threshold models highlight overestimation from high-dose data irrelevant to environmental levels, advocating empirical over precautionary linear assumptions absent confirmation.

Regulatory Framework

United States Controls (FDA and DEA)

The U.S. (FDA) banned safrole from use as a direct or flavoring agent effective December 8, 1960, under the authority of the Federal Food, Drug, and Cosmetic Act, following rodent studies demonstrating hepatocarcinogenic effects at high doses. This prohibition, codified in 21 CFR § 189.180, extends to products containing safrole above trace levels (e.g., 0.002% in finished food), rendering commercial sassafras oil for culinary purposes safrole-free through extraction or debarking processes. The FDA's determination relied on data from the showing liver tumor induction in rats administered safrole at doses equivalent to 100–400 mg/kg body weight daily for extended periods, though human exposure levels from historical food uses were orders of magnitude lower. The (DEA) designates safrole as a List I chemical under the (21 U.S.C. § 802(34)), subjecting its manufacture, distribution, importation, and exportation to strict regulatory oversight due to its established role as a key precursor in the clandestine synthesis of , a Schedule I controlled substance. Handlers exceeding de minimis thresholds (e.g., 1 kg domestic sales or 500 g imports) must register with the DEA, maintain detailed records for two years, report suspicious transactions, and comply with import/export notifications via DEA Form 236. Essential oils exceeding 4% safrole concentration are similarly regulated, with the DEA issuing advisories on diversion risks from sassafras oil sources, as evidenced by seizures linked to production laboratories. Violations can result in criminal penalties, including fines up to $250,000 and imprisonment up to 10 years for first offenses involving precursor diversion.

International Regulations and Variations

Safrole is classified as a substance in Table I of the 1988 Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, subjecting it to international controls aimed at preventing its diversion for the illicit production of amphetamine-type stimulants such as . Parties to the convention, which include nearly all UN member states, are required under Article 12 to establish regulatory measures including licensing for manufacture, trade monitoring, import/export authorizations, and penalties for illicit activities to curb precursor diversion. The (INCB) oversees compliance through pre-export notifications and annual reporting of seizures and legitimate trade. In the , safrole is designated as a Category 1 drug precursor under Council Regulation (EC) No 273/2004, mandating strict licensing, record-keeping, and suspicion-based reporting for handlers to prevent misuse in synthesis. For food use, safrole is prohibited as a substance under Regulation (EC) No 1334/2008, Annex III, due to its genotoxic and carcinogenic potential, with maximum residue levels set at trace amounts (e.g., 20 mg/kg in certain spices like , but as an intentional additive). This reflects a precautionary approach harmonized across member states, contrasting with less stringent natural occurrence allowances in non-EU contexts. Canada prohibits safrole in foods under the Food and Drug Regulations, listing it among adulterating substances that render products unsafe for consumption, with no permitted levels for addition or sassafras-derived extracts. As a precursor, it falls under controlled substances aligned with UN scheduling, requiring permits for import/export. In Australia, safrole is regulated as a precursor by the Office of Drug Control, with trade controls mirroring UN requirements, but food and medicine uses allow limited concentrations—up to 0.1% in internal-use listed medicines and 1% for topical applications—provided they comply with safety assessments, though it has been phased out from most flavor applications. Enforcement variations persist in safrole-producing regions of , where natural sources like parthenoxylon yield high-safrole oils harvested for both legitimate trade and diversion to clandestine MDMA labs; countries such as and have implemented export licensing and harvesting quotas, but weak oversight has led to significant illicit production and , as reported in INCB assessments. These disparities highlight challenges in uniform application, with developing nations facing capacity gaps despite treaty obligations.

Controversies and Scientific Debates

Validity of Carcinogenicity Classification

The International Agency for Research on Cancer (IARC) classifies safrole as Group 2B, "possibly carcinogenic to humans," based on sufficient evidence of carcinogenicity in experimental animals but inadequate evidence in s. This classification stems from studies demonstrating liver tumors in s following oral administration, including hepatocellular carcinomas in mice at doses up to 680 mg/kg body weight daily and in rats at 170-340 mg/kg, with safrole undergoing metabolic activation via enzymes to form reactive 1'-hydroxysafrole intermediates that bind . The U.S. National Toxicology Program similarly lists safrole as "reasonably anticipated to be a human carcinogen" on the same animal data foundation, noting genotoxic effects like formation in livers. Critiques of the classification highlight its reliance on high-dose studies irrelevant to typical exposures, such as trace levels in teas or spices, where doses exceed equivalents by orders of magnitude (e.g., 5000 mg/kg in some trials versus daily intakes). epidemiological data remain sparse and inconclusive, with no direct links to cancer from dietary safrole; purported associations with oral in Asian quid users are confounded by co-exposures to potent carcinogens like alkaloids and . Species-specific metabolic differences further question extrapolability: exhibit higher bioactivation to carcinogenic sulfates via P450 2A6 and lower (e.g., to 1'-oxosafrole) compared to humans, where computational models predict reduced proximate formation and clearance. Proponents of the classification emphasize safrole's across models, including induction and RNA/DNA adducts , arguing no safe threshold exists for genotoxicants under precautionary frameworks. However, the absence of positive carcinogenicity data despite historical uses (e.g., in beverages pre-1960) and weak potency in adult —contrasted with higher activity only in preweanling mice—suggests the may be overstated for low-dose scenarios, prioritizing animal analogies over causal evidence. Re-evaluation could incorporate physiologically based kinetic modeling to refine relevance, as current listings reflect 1970s-1980s data without modern interspecies insights.

Precautionary Bans vs. Empirical Risk

The U.S. Food and Drug Administration banned safrole as a food additive on December 3, 1960, following rodent studies demonstrating hepatocarcinogenicity at doses ranging from 100 to 600 mg/kg body weight per day, which induced liver tumors after chronic exposure. This action was mandated by the Delaney Clause of the 1958 Food Additives Amendment, which prohibits approval of any additive shown to cause cancer in animals or humans, irrespective of dose, exposure context, or species extrapolation uncertainties. The clause reflects a precautionary regulatory philosophy, assuming no safe threshold for carcinogens and prioritizing theoretical risk avoidance over quantitative risk assessment, even when human exposures—such as historical levels in sassafras tea or root beer, estimated at under 1 mg per serving—were orders of magnitude below those eliciting tumors in animals. Empirical assessments of safrole's human risk reveal no documented cases of cancer attributable to typical dietary or environmental exposures, with classifications by agencies like the National Toxicology Program designating it as "reasonably anticipated" to be carcinogenic based solely on animal data, lacking sufficient human epidemiological evidence. Rodent studies required metabolic activation to form proximate carcinogens like 1'-hydroxysafrole, but human efficiency varies, and no population-level associations with have emerged despite widespread historical use in beverages and traditional medicines. Dose-response analyses indicate that carcinogenic effects in animals occur at levels equivalent to humans consuming implausibly high quantities (e.g., 500–1,000 mg/kg body weight daily, far exceeding natural product intakes), supporting arguments for potential thresholds below which risk is negligible, contrary to zero-tolerance policies. Critics of precautionary bans argue that such measures overlook causal realism in , where high-dose animal models often overestimate human hazard due to nonlinear and species-specific detoxification pathways, as evidenced by safrole's weak profile and absence of tumors in low-dose regimens. Regulatory persistence in bans, despite updated reviews affirming limited human data, exemplifies institutional caution amplified by liability concerns and advocacy influences, potentially stifling empirical reevaluation; for instance, related compounds like remain approved at low levels without analogous restrictions. This tension highlights broader debates in , where precautionary defaults may impose disproportionate costs on low-risk substances without commensurate gains.

Impacts on Traditional Practices and Industry

Native American tribes traditionally utilized sassafras root and bark to prepare teas for treating infections, gastrointestinal disorders, , and as a blood purifier. European colonists adopted these practices, employing sassafras in teas and as a for early formulations in the . The FDA's 1960 prohibition on safrole in food additives ended the commercial use of safrole-containing sassafras in , prompting manufacturers to reformulate recipes with synthetic flavors or alternative botanicals like sarsaparilla to mimic the original taste. This regulatory action extended to sassafras tea, with commercial sales banned in 1976 due to high safrole concentrations. Traditional home preparation of tea as a spring tonic persisted in some rural Appalachian communities despite health warnings, though at reduced prevalence following reports of safrole's carcinogenicity in studies. In the flavor industry, the ban necessitated the development of safrole-depleted sassafras extracts for permissible applications in non-food products like perfumes and soaps, while food sectors fully transitioned to artificial substitutes. The market adapted by producing safrole-free variants to comply with safety standards, maintaining limited demand for sassafras-derived fragrances outside ingestible uses. Overall, these restrictions curtailed the economic viability of harvesting for traditional flavoring, shifting small-scale producers toward regulated extraction methods or alternative crops.

References

  1. https://pubchem.ncbi.nlm.nih.gov/compound/Safrole
  2. https://www.ncbi.nlm.nih.gov/books/NBK590823/
  3. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-189/subpart-C/section-189.180
  4. https://ntp.niehs.nih.gov/sites/default/files/ntp/roc/content/profiles/safrole.pdf
  5. https://www.deadiversion.usdoj.gov/chem_prog/advisories/safrole.html
  6. https://www.sigmaaldrich.com/US/en/product/sigma/s9652
  7. https://www.chemspider.com/Chemical-Structure.13848731.html
  8. https://cameochemicals.noaa.gov/chemical/16079
  9. https://www.chemicalbook.com/ChemicalProductProperty_US_CB4365927.aspx
  10. https://www.sciencemadness.org/smwiki/index.php/Safrole
  11. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/isosafrole
  12. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/safrole
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC6197894/
  14. https://open.clemson.edu/cgi/viewcontent.cgi?article=2345&context=all_theses
  15. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/sassafras
  16. https://img.perfumerflavorist.com/files/base/allured/all/document/2016/03/pf.9318.pdf
  17. https://www.scielo.br/j/qn/a/whKRwzwsgkyTDHf7HWJVwRb/
  18. https://www.sciencedirect.com/science/article/pii/S1878535211002553
  19. https://www.researchgate.net/figure/Percentage-content-of-safrole-found-in-the-essential-oil-from-leaves-of-P-divaricatum_tbl1_262749330
  20. https://www.sciencedirect.com/topics/medicine-and-dentistry/safrole
  21. https://www.sciencedirect.com/science/article/abs/pii/S0379073813002028
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC12242330/
  23. https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2023.1230664/full
  24. https://www.researchgate.net/figure/Important-steps-of-the-phenylpropanoid-pathway-in-the-formation-of-methyleugenol_fig5_348291890
  25. https://portal.nifa.usda.gov/web/crisprojectpages/1032493-understanding-the-biosynthesis-of-volatile-phenylpropenes-with-multifaceted-values.html
  26. https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-020-07266-7
  27. https://www.mskcc.org/cancer-care/integrative-medicine/herbs/sassafras
  28. https://foodprint.org/real-food/sassafras-and-file/
  29. https://www.webmd.com/vitamins/ai/ingredientmono-674/sassafras
  30. https://www.myspicer.com/the-history-of-sassafras/
  31. https://www.bellarmine.edu/faculty/drobinson/sassafras.asp
  32. https://www.fao.org/4/v5350e/v5350e.pdf
  33. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/sassafras-albidum
  34. https://blog.tangent.com/Resources/nApAz8/4OK089/history__of-root-beer.pdf
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC8122868/
  36. https://patents.google.com/patent/US4157333A/en
  37. https://victoriasforestsbushfireheritage.com/2024/09/19/sassafras-oil/
  38. https://www.researchgate.net/publication/284686300_Safrole_alternatives_for_industrial_production
  39. https://www.deadiversion.usdoj.gov/schedules/orangebook/f_chemlist_alpha.pdf
  40. https://www.cargohandbook.com/Sassafras_Oil
  41. https://run.unl.pt/bitstream/10362/61276/1/Cardoso_2017.pdf
  42. https://patents.google.com/patent/WO2008138084A2/en
  43. https://www.tni.org/en/article/harvesting-trees-to-make-ecstasy-drug
  44. https://patents.google.com/patent/CN103833722B/en
  45. https://pubs.acs.org/doi/10.1021/acsomega.1c05520
  46. https://www.euda.europa.eu/publications/eu-drug-markets/mdma/production_en
  47. https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=91014TUN.TXT
  48. https://onlinelibrary.wiley.com/doi/abs/10.1002/ffj.3521
  49. https://www.academia.edu/12655725/Piper_hispidinervum_A_Sustainable_Source_of_Safrole
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC8164802/
  51. https://meshb.nlm.nih.gov/record/ui?ui=D012451
  52. https://www.euda.europa.eu/publications/drug-profiles/mdma_en
  53. https://www.[researchgate](/page/ResearchGate).net/publication/270219373_Sassafras_oils_as_precursors_for_the_production_of_synthetic_drugs_Profiling_via_MEKC-UVD
  54. https://www.sciencedirect.com/science/article/abs/pii/S2468170921000370
  55. https://www.deaecom.gov/chem_prog/advisories/docs/Safrole-Notice-Pink-4-30-25-FINAL.pdf
  56. https://www.deadiversion.usdoj.gov/GDP/%28DEA-DC-054%29%28EO-DEA168%29_Chemical_Handler%27s_Manual_Final_%28OMB_Approved%29.pdf
  57. https://www.justice.gov/sites/default/files/open/legacy/2014/05/09/2004-chemical-handlers-manual.pdf
  58. https://www.sciencedirect.com/science/article/abs/pii/S0379073805006900
  59. https://www.drugscience.org.uk/the-superman-pill-deaths-are-the-result-of-our-illogical-drugs-policy
  60. https://www.sciencedirect.com/science/article/abs/pii/0300483X77900397
  61. https://pubmed.ncbi.nlm.nih.gov/14422/
  62. https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0773.1983.tb01088.x
  63. https://pubmed.ncbi.nlm.nih.gov/6846029/
  64. https://www.sciencedirect.com/science/article/abs/pii/S1383571811002798
  65. https://pubs.acs.org/doi/10.1021/tx040001v
  66. https://pubmed.ncbi.nlm.nih.gov/15377158/
  67. https://pubs.acs.org/doi/abs/10.1021/tx030055p
  68. https://www.mdpi.com/2072-6651/15/2/94
  69. https://pubmed.ncbi.nlm.nih.gov/36828409/
  70. https://pubmed.ncbi.nlm.nih.gov/15310247/
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC9962551/
  72. https://academic.oup.com/toxsci/article/128/2/301/1650534
  73. https://www.inchem.org/documents/jecfa/jecmono/v16je22.htm
  74. https://ec.europa.eu/food/fs/sc/scf/out116_en.pdf
  75. https://aacrjournals.org/cancerres/article/33/3/590/479204/1-Hydroxysafrole-a-Proximate-Carcinogenic
  76. https://pubmed.ncbi.nlm.nih.gov/22024337/
  77. https://www.sciencedirect.com/science/article/abs/pii/S0300483X11004392
  78. https://www.researchgate.net/publication/51742572_Comprehensive_toxicity_study_of_safrole_using_a_medium-term_animal_model_with_gpt_delta_rats
  79. https://aacrjournals.org/cancerres/article/37/6/1883/481991/Carcinogenic-and-Mutagenic-Activities-of-Safrole-1
  80. https://aacrjournals.org/cancerpreventionresearch/article/8/1/1/50342/Toxic-Phytochemicals-and-Their-Potential-Risks-for
  81. https://academic.oup.com/carcin/article/20/12/2331/2529859
  82. https://www.sciencedirect.com/science/article/abs/pii/S138357180400004X
  83. http://blog.vanhove.fr/wp-content/uploads/2014/11/Safrole-human-carcinogenicity.pdf
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC1569423/
  85. https://www.ecfr.gov/current/title-21/chapter-II/part-1310/section-1310.02
  86. https://www.unodc.org/pdf/india/publications/precursor_Training_Manual/06_sectionthree.pdf
  87. https://www.incb.org/documents/PRECURSORS/RED_LIST/2020/Red_List_2020_E.pdf
  88. https://www.unodc.org/pdf/convention_1988_en.pdf
  89. https://www.incb.org/incb/en/precursors/tables.html
  90. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:02008R1334-20220926
  91. https://lois.justice.gc.ca/eng/regulations/C.R.C.%2C_c._870/section-B.01.046-20060322.html
  92. https://www.odc.gov.au/controlled-substances/list/safrole
  93. https://www.tga.gov.au/products/medicines/non-prescription-medicines/listed-medicines/compliance-and-education-listed-medicines/listed-medicines-risk-containing-safrole
  94. https://monographs.iarc.who.int/wp-content/uploads/2018/09/ClassificationsAlphaOrder.pdf
  95. https://www.inchem.org/documents/iarc/vol10/safrole.html
  96. https://www.mdpi.com/2304-8158/11/18/2828
  97. https://www.sciencedirect.com/science/article/abs/pii/S027869152300090X
  98. https://food.ec.europa.eu/document/download/7f094663-7233-41e1-a05b-50479ca1bda5_en?filename=fs_food-improvement-agents_flavourings-out188.pdf
  99. https://www.gao.gov/assets/hrd-82-3.pdf
  100. https://www.peacehealth.org/medical-topics/id/hn-3661007
  101. https://www.adkinsarboretum.org/programs_events/ipp/sassafras.html
  102. https://www.outdoorapothecary.com/the-magic-and-medicine-of-sassafras/
  103. https://www.historyoasis.com/post/history-root-beer
  104. https://www.medicinenet.com/why_is_sassafras_banned/article.htm
  105. https://www.latimes.com/archives/la-xpm-2005-feb-14-he-supp14-story.html
  106. https://naturespoisons.com/2014/09/17/a-scientist-stole-my-root-beer-safrole-sassafras/
  107. https://www.arogreen.com/safrole-free-essential-oils-for-the-safety-of-your-products-how-do-we-do-it/
  108. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/sassafras
Add your contribution
Related Hubs
User Avatar
No comments yet.